SG11202105685TA - Methods and materials for increasing transcription factor eb polypeptide levels - Google Patents

Methods and materials for increasing transcription factor eb polypeptide levels

Info

Publication number
SG11202105685TA
SG11202105685TA SG11202105685TA SG11202105685TA SG11202105685TA SG 11202105685T A SG11202105685T A SG 11202105685TA SG 11202105685T A SG11202105685T A SG 11202105685TA SG 11202105685T A SG11202105685T A SG 11202105685TA SG 11202105685T A SG11202105685T A SG 11202105685TA
Authority
SG
Singapore
Prior art keywords
alkyl
independently selected
optionally substituted
alkylene
substituents independently
Prior art date
Application number
SG11202105685TA
Other languages
English (en)
Inventor
Beibei Chen
Toren Finkel
Yuan Liu
Original Assignee
Univ Pittsburgh Commonwealth Sys Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh Commonwealth Sys Higher Education filed Critical Univ Pittsburgh Commonwealth Sys Higher Education
Publication of SG11202105685TA publication Critical patent/SG11202105685TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202105685TA 2019-01-03 2020-01-03 Methods and materials for increasing transcription factor eb polypeptide levels SG11202105685TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962788049P 2019-01-03 2019-01-03
US201962879374P 2019-07-26 2019-07-26
PCT/US2020/012268 WO2020142748A1 (en) 2019-01-03 2020-01-03 Methods and materials for increasing transcription factor eb polypeptide levels

Publications (1)

Publication Number Publication Date
SG11202105685TA true SG11202105685TA (en) 2021-06-29

Family

ID=71406977

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105685TA SG11202105685TA (en) 2019-01-03 2020-01-03 Methods and materials for increasing transcription factor eb polypeptide levels

Country Status (12)

Country Link
US (2) US12286442B2 (cg-RX-API-DMAC10.html)
EP (1) EP3906033A4 (cg-RX-API-DMAC10.html)
JP (1) JP7566753B2 (cg-RX-API-DMAC10.html)
KR (1) KR102904932B1 (cg-RX-API-DMAC10.html)
CN (1) CN113316453B (cg-RX-API-DMAC10.html)
AU (1) AU2020204717B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021012950A2 (cg-RX-API-DMAC10.html)
CA (1) CA3123902A1 (cg-RX-API-DMAC10.html)
IL (1) IL284403A (cg-RX-API-DMAC10.html)
MX (1) MX2021008152A (cg-RX-API-DMAC10.html)
SG (1) SG11202105685TA (cg-RX-API-DMAC10.html)
WO (1) WO2020142748A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4178955A1 (en) 2020-07-11 2023-05-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CZ309449B6 (cs) * 2020-12-24 2023-01-25 Ústav experimentální botaniky AV ČR, v. v. i. Chinazolinové deriváty jako selektivní inhibitory cyklooxygenázy-1
CN113248518B (zh) * 2021-06-21 2022-03-25 山东大学 嘧啶哌嗪类衍生物及其制备方法与应用
CN121941701A (zh) * 2023-07-28 2026-04-28 特兰埃克斯公司 用于治疗溶酶体病症的突变tfeb
CN119818678A (zh) * 2024-12-24 2025-04-15 广州医科大学附属妇女儿童医疗中心 Tfeb在制备变应性鼻炎的药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
AU2001290912A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US20030158195A1 (en) * 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
US7198926B2 (en) 2003-05-08 2007-04-03 E. I. Du Pont De Nemours And Company Preparation of (E)- and (Z)-2-methyl-2-butenoic acids
JP2006528694A (ja) 2003-05-13 2006-12-21 スミスクライン ビーチャム コーポレーション ナフチリジンインテグラーゼインヒビター
WO2008157500A1 (en) 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
WO2009062118A2 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
US8604049B2 (en) * 2008-08-05 2013-12-10 Boehringer Ingelheim International Gmbh 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments
JP2011529932A (ja) * 2008-08-05 2011-12-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ナフチリジン及び医薬としてのその使用
GB201007203D0 (en) * 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
RU2015120217A (ru) 2012-11-20 2017-01-10 Ф. Хоффманн-Ля Рош Аг Замещенные 1,6-нафтиридины
EP4026545A1 (en) 2014-11-19 2022-07-13 Rush University Medical Center Compositions and methods for treating lysosomal disorders
EP3538091A4 (en) * 2016-11-08 2020-06-10 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE MTORC INHIBITORS AND USES THEREOF
WO2018089433A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL mTORC INHIBITORS AND USES THEREOF
WO2018089493A1 (en) * 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PYRROLE mTORC INHIBITORS AND USES THEREOF
WO2018191146A1 (en) * 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof

Also Published As

Publication number Publication date
IL284403A (en) 2021-08-31
MX2021008152A (es) 2021-10-13
CN113316453A (zh) 2021-08-27
JP2022516631A (ja) 2022-03-01
KR102904932B1 (ko) 2025-12-26
JP7566753B2 (ja) 2024-10-15
EP3906033A1 (en) 2021-11-10
BR112021012950A2 (pt) 2021-09-14
KR20210111787A (ko) 2021-09-13
US20220112218A1 (en) 2022-04-14
US20250382309A1 (en) 2025-12-18
WO2020142748A1 (en) 2020-07-09
EP3906033A4 (en) 2022-11-09
CN113316453B (zh) 2025-12-23
US12286442B2 (en) 2025-04-29
AU2020204717B2 (en) 2025-01-16
CA3123902A1 (en) 2020-07-09
AU2020204717A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
IL284403A (en) Methods and materials for increasing EB transcription factor polypeptide levels
GB2587328B (en) Composite materials and methods
EP4041241A4 (en) METHODS OF TREATING MYELOFIBROSIS AND ASSOCIATED CONDITIONS
SG11202103024RA (en) Culture material and use thereof
EP4021928A4 (en) MODIFIED N-810 AND ASSOCIATED METHODS
IL287318A (en) Materials and methods for the production of proteins
IL290840A (en) Preparations and methods for altering cd123
PL3938074T3 (pl) Wkład mineralizujący i sposób jego eksploatacji
IL290109A (en) Cells for enhanced immune healing and their uses
EP4026382B8 (en) Methods and apparatuses for sidelink operations
ZA202210284B (en) Anti-trem1 antibodies and related methods
GB201906433D0 (en) Detector and method
PL3736095T3 (pl) Materiał w kształcie płyty i sposób jego produkcji
PT3975780T (pt) Parte superior e método de fabrico de uma parte superior
GB2587469B (en) Inceptor and method
EP4082767A4 (en) REINFORCEMENT MATERIAL AND REINFORCEMENT STRUCTURE
GB201911130D0 (en) MAterials and methods
GB201911141D0 (en) Materials and method
HK40061391A (en) Methods and materials for increasing transcription factor eb polypeptide levels
HUE064733T2 (hu) Klórral módosított széntartalmú anyag
GB2579687B (en) Composition and method
IL289564A (en) Modified cells and related methods
GB201911629D0 (en) Materials and methods
GB201911133D0 (en) Materials and methods
GB201911135D0 (en) Materials and methods